March 19, 2018 8:39am

No events of cancer relapse and No ProTmune-related adverse events reported by investigators as shares closed Friday down -$0.04 to $11.83 and are up – pre-open +$0.53 or +4.48% to $12.36 - BUY


 

The data is being featured in a poster presentation at the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation being held in Lisbon, Portugal, March 18-21, 2018.

“The primary objective of hematopoietic cell transplantation for cancer patients is disease-free survival. We are very encouraged that no events of cancer relapse have occurred with ProTmune in the P1 stage of PROTECT,” said Chris Storgard, M.D., Chief Medical Officer of Fate Therapeutics.

  • Clinical findings underscore the compelling safety profile of ProTmune and suggest that ProTmune has the unique potential to attenuate early, life-threatening events of acute GvHD and promote the curative potential of allogeneic transplant. 

 

Seven adult subjects with hematologic malignancies undergoing matched unrelated donor hematopoietic cell transplantation (HCT) received ProTmune as the hematopoietic cell graft in the P1 stage of PROTECT.

  • As of a February 26, 2018 data cut-off, there have been no events of cancer relapse with a median time on study of 228 days.
  • Additionally, no serious adverse events related to ProTmune have been reported by investigators.
  • The randomized, controlled and double-blinded P2 stage of PROTECT is currently enrolling up to 60 subjects at 14 U.S. centers.

 

FATE is developing ProTmune as a preventative therapy to reduce the incidence and severity of acute graft-versus-host disease (GvHD) by Day 100 following HCT.

Acute GvHD is the leading cause of early morbidity and mortality following allogeneic HCT. Extended use of immunosuppressive agents to treat acute GvHD compromises the anti-leukemia activity of the transplant procedure and significantly increases the risk of cancer relapse and mortality.